You are now leaving www.admabiologics.com
The link you have selected will take you outside of ADMA Biologics corporate website. The site you will be entering is intended for U.S. audiences only. Do you wish to continue?
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
REVENUES: | ||||
Product revenue | $ 10,240,650 | $ 7,186,795 | $ 28,156,571 | $ 17,204,909 |
License revenue | 35,708 | 35,708 | 107,125 | 107,125 |
Total Revenues | 10,276,358 | 7,222,503 | 28,263,696 | 17,312,034 |
OPERATING EXPENSES: | ||||
Cost of product revenue (exclusive of amortization expense shown below) | 11,855,464 | 7,916,220 | 42,180,319 | 27,812,635 |
Research and development | 1,708,391 | 491,404 | 4,893,549 | 1,879,025 |
Plasma center operating expenses | 1,218,898 | 456,899 | 2,597,444 | 1,705,498 |
Amortization of intangible assets | 178,838 | 211,235 | 536,514 | 633,704 |
Selling, general and administrative | 9,115,744 | 7,197,173 | 25,750,458 | 18,878,690 |
Total operating expenses | 24,077,335 | 16,272,931 | 75,958,284 | 50,909,552 |
LOSS FROM OPERATIONS | (13,800,977) | (9,050,428) | (47,694,588) | (33,597,518) |
OTHER INCOME (EXPENSE): | ||||
Interest and other income | 1,164 | 281,896 | 268,643 | 619,103 |
Interest expense | (3,091,200) | (2,649,404) | (8,875,597) | (6,262,489) |
Loss on extinguishment of debt | 0 | 0 | 0 | (9,962,495) |
Gain on transfer of plasma center assets | 0 | 0 | 0 | 11,527,421 |
Other expense, net | (26,440) | (20,523) | (39,232) | (42,308) |
Other income expense, net | (3,116,476) | (2,388,031) | (8,646,186) | (4,120,768) |
NET LOSS | $ (16,917,453) | $ (11,438,459) | $ (56,340,774) | $ (37,718,286) |
BASIC AND DILUTED LOSS PER COMMON SHARE | $ (0.19) | $ (0.19) | $ (0.68) | $ (0.72) |
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||
Basic and Diluted | 87,698,258 | 59,317,830 | 82,627,753 | 52,673,190 |